MARKHAM, ON, Oct. 15 /PRNewswire/ - Cytochroma today announced that it has appointed John Cunningham, CVO, BM BCh, DM, FRCP, to the Company's Scientific Advisory Board.
Dr. Cunningham is Professor of Nephrology at the UCL Medical School, London and Consultant Nephrologist at the Royal Free Hospital, London. His early training was at Cambridge and Oxford Universities, with postgraduate training in The University of London and
"We are delighted and honored that Dr. Cunningham has agreed to advise Cytochroma on its efforts to develop new drugs for secondary hyperparathyroidism in chronic kidney disease patients," said Charles W. Bishop, Ph.D., President and Chief Executive Officer of Cytochroma. "Dr. Cunningham's wealth of knowledge and clinical experience will be invaluable as we move our products through mid- and late-stage clinical trials."
Other members of Cytochroma's Scientific Advisory Board include: - Geoff Block, MD - Director of Clinical Research, Denver Nephrology - David Allen Bushinsky, MD - Professor of Medicine and of Pharmacology and Physiology, University of Rochester School of Medicine, and Chief, Nephrology Division, University of Rochester Medical Center - Russell Chesney, MD - Le Bonheur Professor and Chair, Department of Pediatrics, University of Tennessee Health Science Center - Bess Dawson-Hughes, MD - Professor of Medicine, Tufts University School of Medicine, and Senior Scientist and Director, Bone Metabolism Laboratory Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University - Glenville Jones, PhD - Head of Biochemistry Department, Professor of Biochemistry & Medicine, Queen's University, Kingston, Ontario - Kevin Martin, MD - Director of Research, Division of Nephrology, St. Louis University School of Medicine - L. Darryl Quarles, MD - Vice Chairman for Research, Department of Internal Medicine, and Director, The Kidney Institute and Division of Nephrology at the University of Kansas Medical Center - Isidro Salusky, MD - Professor of Pediatric Medicine, David Geffen School of Medicine, and Director of Clinical Research Center, UCLA School of Medicine - Stuart Sprague, MD - Professor of Medicine, Feinburg School of Medicine, and Chief, Division of Nephrology & Hypertension, Evanston Northwestern Healthcare, Northwestern University About Cytochroma
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three lead product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.
Copyright©2009 PR Newswire.
All rights reserved